Skip to main content
Premium Trial:

Request an Annual Quote

UCSF Licenses Heart Gene IP from Celera

NEW YORK (GenomeWeb News) – Celera said today that the University of California, San Francisco has licensed the rights to use Celera’s KIF6 gene-related intellectual property to develop an in-house test for cardiovascular risk and statin benefit.

The agreement makes UCSF the first lab in the US besides Celera’s Berkeley HeartLab subsidiary to use the Celera discoveries.

Studies have shown an association between KIF6, which encodes a kinesin-like protein 6, and cardiovascular risk and statin benefit.

Under the agreement, UCSF will be allowed to develop and perform a test using KIF6 for three years in California.

Celera CEO Kathy Ordonez said in a statement that the agreement is “consistent with Celera’s strategy to make KIF6 testing broadly available and our efforts to drive our new genetic discoveries into routine personalized care for patients with risk for cardiovascular disease."

Financial terms of the agreement were not released.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.